India sends delegation to 78th World Health Assembly, reaffirms commitment to global health cooperation
Geneva [Switzerland], May 19 (ANI): Reaffirming its commitment towards global health cooperation, India has sent a delegation to participate in the 78th World Health Assembly commencing in Geneva, the Ministry of Health and Family Welfare (MoHFW), shared on Monday.
Providing the details in a post on X, the MoHFW said that the Indian delegation is being led by Punya Salila Srivastava, Secretary, Ministry of Health & Family Welfare.
It further noted that India's participation reflects the continued commitment towards strengthening global health systems and advancing international collaboration.
'Today marks the commencement of the 78th World Health Assembly in Geneva. The Indian delegation, led by Ms. Punya Salila Srivastava, Secretary, Ministry of Health & Family Welfare, Government of India, is actively participating in the Assembly, reflecting India's continued commitment to strengthening global health systems and advancing international collaboration.'
https://x.com/MoHFW_INDIA/status/1924360194412490844
As per the World Health Organisation, the 78th World Health Assembly is being held in Geneva from May 19-27. The theme of this year's Health Assembly is, 'One World for Health.'
Notable highlights from the 78th Session would include, May 19 that marks the opening og the Assembly, with deliberations on the Pandemic Agreement in the afternoon.
On May 20, it is expected that the adoption of the Pandemic Agreement would take place along with a discussion on the Proposed Programme Budget 2026-2027.
May 21 would see a Ministerial Roundtable on data and sustainable financing and May 23 would see the presentation of the public health prizes and awards, the details were shared by WHO in an earlier post on X.
The most recent update has been the election of Dr Teodoro Javier Herbosa from the Philippines as President of the 78th World Health Assembly.
https://x.com/WHO/status/1924369347562127380
At the World health assemsbly, member States and the WHO Secretariat will have to reconcile a significant funding shortfall ahead of the next two-year programme budget. While fully funding WHO's growing mandate of work has long faced challenges, the United States' intended withdrawal from the Organization has further strained the budget. A planned 20% increase in mandatory member contributions that was years in the making will be up for adoption at WHA78, offering a potential boost--but in a constrained fiscal climate, its approval is uncertain. Broader governance and staffing reforms will also be on the agenda. (ANI)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
43 minutes ago
- Business Standard
Indian pharma market grows 7.2% in May led by chronic therapies
Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches Sanket Koul New Delhi The Indian Pharma Market (IPM) grew 7.2 per cent in May this year with almost all major therapies showing positive growth, according to market research firm Pharmarack. Data suggest that big chronic therapies such as cardiac and anti-infectives, which account for nearly 25 per cent of the overall domestic market, recorded value growth of 11.7 per cent and 7.6 per cent, respectively. On the other hand, several smaller supergroups such as urology and antineoplastics, which made up 2 per cent each of the IPM's sales value for the month, also recorded double-digit growth in May at 12.3 per cent and 11.7 per cent, said Sheetal Sapale, vice-president, commercial, Pharmarack. Data suggest that the overall value growth for the IPM in May was driven by price growth and new introductions. The IPM also reported a minuscule 0.4 per cent unit growth during the month, with the chronic segments such as antidiabetics (6.1 per cent) and cardiac (4.8 per cent) performing better than the overall market figure. Experts believe that the antidiabetic segment saw a 6.1 per cent rise in volume in May due to a key drug, empagliflozin, going off-patent, as companies launched several plain and combination medications in the segment. Growth in the moving annual turnover (MAT) for the IPM between June 2024 and May 2025 stood at 8.1 per cent, leading to a total turnover of over Rs 2.29 trillion, while volumes in the domestic market grew by 1.1 per cent. The MAT of leading therapy areas such as cardiac, gastrointestinal and anti-infectives, which constitute around 38 per cent of the pharmaceutical market, showed robust volume growth at 10.4 per cent, 9.5 per cent and 6.5 per cent, respectively. While the top 20 brands in the IPM registered modest monthly value growth in the domestic market during the month, Sun Pharma and Dr Reddy's posted significant monthly value growth at 11.2 per cent each. They were followed by Torrent Pharma and Ipca Laboratories at 10.8 per cent, and Alkem Laboratories at 10.3 per cent monthly value growth. According to Pharmarack data, GlaxoSmithKline's (GSK) antibiotic medication Augmentin and USV's anti-diabetic drug Glycomet GP continued to be the top-selling medicine brands at the MAT level, with sales worth Rs 819 crore and Rs 810 crore, respectively.
Indian Express
an hour ago
- Indian Express
India has to maintain global regulatory standards to remain the pharmacy of the world: Ex DCGI
Former Drugs Controller General of India (DCGI) Dr G N Singh, who is now the Advisor to Uttar Pradesh Chief Minister Yogi Adityanath, was leading an outreach programme in Gujarat for pharmaceutical companies to set up units of the Bulk Drug Pharma Park coming up in Lalitpur district. He spoke to The Indian Express on the sidelines of the country's need to maintain global scientific standards and regulation. Dr Singh also served as the Central Drug Standards Control Organisation (CDSCO) for six years till 2018, and as the Founder-Director of the Indian Pharmacopeia Commission (IPC). Excerpts from the interview: How do you see the development and future of the pharmaceutical manufacturing sector in India? India wants to become self reliant in manufacturing and innovation in bulk drugs. That is why the Prime Minister, over the last few years, has given special emphasis on developing pharma parks across the country. In this context, the UP Chief Minister decided to develop a bulk drug park in his state. And we want to make sure that if any international incident happens, since the geopolitical situation is in a troublesome phase, then we can be self-reliant. In such cases, India has to be ready to address issues like healthcare. We (India) are known as the pharmacy of the world since we supply medicines to more than 200 countries. So we have to see that the continuity of supply of medicines remains undisturbed. When you talk about the geopolitical situation, are you referring to the excessive imports of Active Pharmaceutical Ingredients (APIs) from China? Majority of our APIs are being imported from China. It is the thinking of experts at the highest level that India has to be fully self-reliant. We are, but due to cost prohibition, we were lacking in API production. Now with bulk drug parks coming up, the cost of production will also come down and we will become competitive in the international market and hopefully begin supplying APIs to many others, especially Europe and other developed markets. We will capture those markets based on quality, prices and uninterrupted supply. There have been complaints coming in from many nations, including Africa and Europe and ones flagged by the USFDA, regarding the quality of drugs going out from India. How do you see this in context of the way 'made-in-India' medicines are perceived abroad? As scientific systems are developing, the regulatory landscape is also changing. We are continuously adjusting the regulatory system so that the regulator meets the expectations of scientific rigour and the people. Safety, efficacy and quality of medicines is of paramount importance to the regulator and to end users everywhere. So, we want to make a harmonised approach so none of the issues lag behind the science requirements. Both the Drugs and Cosmetics Rules and the Indian Pharmacopeia (IP), which is the book of standards for drugs, are continously being upgraded to address these issues. So, does the Indian drug regulator need more teeth? Is stricter regulation required today? The requirement is to strengthen the drug regulatory system in terms of science, in terms of manpower, in terms of the execution of mechanism and the government must be thinking on those lines because it is aware of these issues. If we want to remain the pharmacy of the world we need to maintain the standards of global science and regulation. The most recent debate is regarding generic drugs. There have been problems highlighted with regards to bioequivalence studies and doctors are pushing back against compulsorily prescribing them. How do you see this issue? It is only a myth. These issues have been raised multiple times and as a scientist, I am of the firm opinion that the book of standards is the same for branded, branded-generic or generic medication. If you take the Indian, US and UK Pharmacopeias, they are not ascribing different standards. They are all the same — right from manufacturing systems, quality control and testing before batches reach the market. So, I don't agree that generic drugs are in any way less than the branded medicines and it is just a myth with no basis in scientific parameters. They are almost equal in my opinion and I had made it very clear on various forums, including international ones, not just as a former drug regulator of this country, but also as the head of the Indian Pharmacopeia Commission. I appeal to the doctors and to the people to accept generic medicines as ones at par with the branded ones.
The Hindu
an hour ago
- The Hindu
Supply shortage forces SCTIMST doctors to call off neuro-interventional procedures indefinitely
Shortage or near-total unavailability of necessary materials for neuro Cath laboratories—high-end specialised catheters, stents and specialised soft platinum coils used for endovascular coiling to treat brain aneurysms—has led clinicians at the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) to call off all scheduled neuro-interventional procedures from next week, throwing patient care into disarray. Many patients who were scheduled to undergo interventional procedures from this weekend, after being on the waiting list for long, were informed in the eleventh hour that their procedures were being suspended and that they would have to seek treatment elsewhere. The decision to suspend all peripheral and neuro-interventional procedures at the SCTIMST from June 9 was taken by the doctors at the Department of Imaging Sciences (IS) and Interventional Radiology (IR). They pointed out that they were unable to perform routine and emergency interventional procedures because the manufacturers had withdrawn all supplies from the Cath labs. In a letter to the Director of the SCTIMST on Friday, the doctors said that they had been repeatedly reminding the administration since November 2023 that essential intervention materials for the Cath labs of the IS and IR department were going short. They said that they were using the bare minimum resources to continue doing the neuro-intervention procedures. The doctors pointed out that they had taken up this issue with the administration multiple times and even suggested possible solutions. Yet, 'the current administration had not been able to maintain the operational needs of one of the institute's key departments, one that has played a foundational role in advancing endovascular interventions in the country,' they said. They refused to resume interventional procedures till regular and adequate supply of necessary materials was restored. Mostly imported According to sources, the problem of shortage of supplies arose because the rate contract for medical supplies was not renewed after 2023 and the contract rates were being extended. Most of the materials used for neuro-intervention procedures are imported and after import prices went up, the manufacturers and suppliers refused to continue supplying the same at the rates quoted in 2023. 'The Union government wants all public procurement to go through the Government e-Marketplace (GeM) portal for more streamlined and transparent procurement but there have been many quality concern issues, technical rejections due to non-conformance to specifications and so on, leading to huge delays in procurement. On the other hand, there are no Indian-made substitutes for the kind of Cath lab materials that the IR dept needs. It is unusual for doctors at the SCTIMST to show open defiance but the Radiology department felt that they were driven to the wall,' a senior doctor at the SCTIMST told The Hindu. The SCTIMST administration officials said that till now, as an autonomous institution, the doctors at the SCTIMST had a say regarding purchases. 'However, from May 2023, it is mandatory that all public procurements be made through the GeM portal. The current stalemate over procurement has all to do with the shifting over to the new purchase system. It is very cumbersome and there are many process delays, especially when some of the items that Radiology needs are customised. Our doctors are very upset and it is hurting our patients but we need time to tide over this mess,' an administrative official said. Institute's statement The SCTIMST later issued a statement that due to the ongoing streamlining of the procurement process of interventional devices, 'there will be a rescheduling of certain neuro-interventional procedures.'
